Key result
IonWorks HT successfully screens 300 compounds to identify hERG activity across therapeutic areas.
Why the study?
The FDA recommends assessing new drug candidates for IKr block to prevent torsades de pointes, necessitating effective screening methods for hERG channel interaction.
Answers are grounded in this paper and cite their sources.
May aid preclinical IKr screening in drug development; leaves open clinical translation to arrhythmia prevention.
Several commercially available pharmaceutical compounds have been shown to block the IKr current of the cardiac action potential. This effect can cause a prolongation of the electrocardiogram QT interval and a delay in ventricular repolarization. The Food and Drug Administration recommends that all new potential drug candidates be assessed for IKr block to avoid a potentially lethal cardiac arrhythmia known as torsades de pointes. Direct compound interaction with the human ether-a-go-go- related gene (hERG) product, a delayed rectifier potassium channel, has been identified as a molecular mechanism of IKr block. One strategy to identify compounds with hERG liability is to monitor hERG current inhibition using electrophysiology techniques. The authors describe the Ion Works HT instrument as a tool for screening cell lines expressing hERG channels. Based on current amplitude and stability criteria, a cell line was selected and used to perform a 300-compound screen. The screen was able to identify compounds with hERG activity within projects that spanned different therapeutic areas. The cell line selection and optimization, as well as the screening abilities of the Ion Works HT system, provide a powerful means of assessing hERGactive compounds early in the drug discovery pipeline.
No takes yet. Share an insight, caveat, or question.
Guthrie et al. (2005) studied hERG liability / Torsades de pointes. Ion Works HT instrument was evaluated on Identification of compounds with hERG activity. The Ion Works HT system successfully screened 300 compounds using a selected cell line, identifying compounds with hERG activity across different therapeutic areas.
Synapse has enriched 10 related papers. Consider them for comparative context: